Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATIC | P31939 | 5/20 | 0.62 |
| ▸ | GHSR | Q92847 | 6/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205908 | 0.77 | ATIC (1.00) | ATICGHSRTHRB | |
| SCHEMBL17801533 | 0.68 | ATIC (0.73) | ATICGHSRTHRB | |
| SCHEMBL17801564 | 0.68 | ATIC (1.00) | ATICGHSR | |
| SCHEMBL17801575 | 0.67 | ATIC (0.61) | ATICGHSRTHRB | |
| SCHEMBL17801535 | 0.67 | ATIC (0.51) | ATICGHSRTHRB | |
| SCHEMBL17801631 | 0.61 | ATIC (0.72) | ATICGHSRTHRB | |
| SCHEMBL17801597 | 0.61 | ATIC (0.50) | ATICGHSRTHRB | |
| SCHEMBL19205931 | 0.60 | ATIC (0.72) | ATICGHSRTHRB | |
| SCHEMBL17801616 | 0.55 | ALDH1A1 (0.40) | ATIC | |
| SCHEMBL17801462 | 0.54 | ATIC (0.64) | ATICGHSRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227279-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | Eli Lilly and Company (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016089670-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2016-06-09 | — | — | WO | disclosed |